Friday, March 29, 2024 4:25:03 PM
Name of the Issuer: JNS Holdings Corporation
Check One: Annual Report Quarterly Report Interim Report
For Period Ended: 12/31/2023
Address of Principal Executive Office:
830 Seton Court, Unit 1
Wheeling, IL 60090
Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly
Report could not be filed within the prescribed time period.
The company was not able to complete its accounting for the period ending 12/31/2023 in sufficient time
for management to thoroughly review the report.
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or
Interim Report and 15 calendar days to post an Annual Report.]
April 15, 2024
Person to contact regarding this notification: Officer/Director Signature:
Date: 3/28/2024 Date: 3/28/3024
Signature: /s/ Tim Sittig Signature: /s/ Brian Howe
Name: Tim Sittig Name: Brian Howe
Title: CFO Title: CEO
Instructions to post Notification of Late Filing in www.OTCIQ.com:
1. Fill out this Notification of Late Filing form and convert the file to a PDF
2. Log in to www.OTCIQ.com and click “Add Financial Report” on the left hand navigation
3. Select Dissemination Date “Immediate”
4. Under Report Type, select “Notification of Late Filing”
5. Enter Period End Date corresponding to the quarter/fiscal year end date for which this Notice is being filed
6. Click “Browse” and select the PDF saved in step 1 above.
7. A preview of the document will appear next. Please make sure to review the entire document & scroll down
to click the “Submit” button. Your Notification of Late Filing will appear within a few minutes on otcmarkets.com
Alternative Reporting companies on the Pink Current tier may utilize the Notification of Late Filing to receive
the extension. The Notification must be submitted by the applicable reporting deadline to qualify for the
extension.
OTCQB and OTCQX non-SEC reporting companies may also post this document to remain compliant with
OTC reporting requirements.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM